Ellie McGuire is a managing partner of the Polaris Innovation Fund.
McGuire currently serves on the Boards of Muna Therapeutics, Montis Biosciences, Candesant Biomedical, and Satellite Biosciences. In addition, she was the founding president of Volastra Therapeutics. She is an expert in residence for the Harvard Office of Technology Development.
Prior to co-founding the Polaris Innovation Fund, McGuire was the head of business development at Lyndra. She previously held leadership and consulting positions in business development, operations, and strategy in multiple life science companies including Arsia Therapeutics, Lyndra, and XTuit Pharmaceuticals.
The endorsements of current or past portfolio company executives are provided as illustrative examples and designed to demonstrate the benefits to portfolio companies of partnering with us. These statements are primarily aimed at prospective portfolio companies and not intended to solicit investors. The portfolio companies covered in these endorsements do not represent all portfolio company investments we have made. The experiences highlighted in these testimonials are solely those of the executives profiled and may not necessarily represent or be indicative of the current, past, or future experiences of other portfolio companies. Past results and experiences discussed are not indicative, or a guarantee of future results and experiences. We have not provided cash or other type of compensation in exchange for receiving these endorsements. We do not believe there are typically any material conflicts associated with providing these endorsements. The compensation of our portfolio company executives is primarily driven by the performance of their respective portfolio companies and any discretion we exercise in such compensation determinations is not influenced by whether an executive has provided a favorable statement. Additionally, the economic interests of our portfolio companies’ executives are generally well-aligned with ours and those of our investors. Nevertheless, the fact that these endorsements have been provided by individuals whose compensation we exercise a certain level of control over may incentivize them to provide favorable evaluations of their experiences working with us.